Authors: Renaud Descourt, Maurice Perol, Gaelle Rousseau-Bussac, et. al. Abstract: 9045 Citation: J Clin Oncol 37, 2019 (suppl; abstr 9045) Background: Brigatinib is a next-generation ALK inhibitor initially developed in pre-treated ALK+ NSCLC. Data on the efficacy of brigatinib in real world remain rare. Methods: This retrospective multicentric study analyzed ALK-+...
Pro zobrazení tohoto obsahu je třeba být přihlášen.